thiophenes has been researched along with warfarin in 338 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (2.66) | 18.7374 |
| 1990's | 2 (0.59) | 18.2507 |
| 2000's | 17 (5.03) | 29.6817 |
| 2010's | 308 (91.12) | 24.3611 |
| 2020's | 2 (0.59) | 2.80 |
| Authors | Studies |
|---|---|
| Duffy, EM; Jorgensen, WL | 1 |
| Levy, G; Slattery, JT | 1 |
| De Clerck, F; Reneman, R; Vermylen, J | 1 |
| Inoue, H; Kawada, S; Koide, S; Ogawa, J; Shohtsu, A; Tsurumi, T | 1 |
| Ombetta, JE; Panouse, JJ; Robert, JF; Xicluna, A | 1 |
| Hatsuoka, M; Kashii, A; Sasaki, K; Seiki, M | 1 |
| Takayama, T | 1 |
| Aman, J; Gillberg, BO | 1 |
| Buu-Hoï, NP; Mentzer, C; Roussel-Périn, O | 1 |
| Fang, VS | 1 |
| Boike, S; Forrest, A; Ilson, B; Jorkasky, DK; Kazierad, DJ; Martin, DE; Zariffa, N | 1 |
| Baccichetti, F; Caffieri, S; Dall'Acqua, F; Lucchini, V; Marzano, C; Miolo, G; Rodighiero, P; Vedaldi, D | 1 |
| Angelini, G; Gia, O; Magno, SM; Margonelli, A; Rodighiero, P; Via, LD | 1 |
| Doss, SH; Louca, NA; Wardakhan, WW | 1 |
| Glueck, CJ; Khalil, Q; Wang, P; Winiarska, M | 1 |
| Ma, Q | 1 |
| Eikelboom, JW; Weitz, JI | 1 |
| Eikelboom, JW; Hirsh, J; O'Donnell, M | 1 |
| Chordia, MD; Li, F; Macdonald, TL; Woodling, KA | 1 |
| Go, G; Gonzalez Della Valle, A; Lyman, S; Salvati, EA; Sharrock, NE | 1 |
| Califf, RM; Fox, KA; Mahaffey, KW; Patel, MR; Piccini, JP | 1 |
| Francis, CW | 1 |
| Childers, A; Itoh, K; Kleiner, HE; Li, Y; Prince, M; Yamamoto, M | 1 |
| Drouet, L | 1 |
| Chu, BL; Guo, B; Lin, JM; Wang, Z | 1 |
| Hayden, EC | 1 |
| Chappell, J; He, J; Knadler, MP; Lee, D; Lobo, E; Mitchell, M | 1 |
| Conard, J; Horellou, MH; Samama, MM | 1 |
| Khalabuda, M; McBride, BF; Morell, J; Sullivan, B | 1 |
| Banda, ZK; Benmira, S; Bhattacharya, V | 1 |
| Cohen, AT; Nandini, B; Ota, S; Wills, JO | 1 |
| Duconge, J; Ruaño, G; Seip, RL | 1 |
| Lopes, RD; Mahaffey, KW; Piccini, JP | 1 |
| Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS | 1 |
| Panchenko, EP | 1 |
| Butler, J; Gan, E; Kaplan, Z; Malan, E; Merriman, E; Tran, H | 1 |
| Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P | 1 |
| Minarelli, M; Valgimigli, M | 1 |
| Fleita, DH; Mohareb, RM; Sakka, OK | 1 |
| Mitka, M | 2 |
| Arora, R; Chandrasekar, S; Loomba, R; Shah, P | 1 |
| Dakanali, M; Haidekker, MA; Nipper, ME; Theodorakis, E | 1 |
| Smetana, GW; Srour, JF | 1 |
| Baty, SR; Griffith, CB; Phillippe, HM | 1 |
| Fisher, WD | 1 |
| Burghaus, R; Coboeken, K; Gaub, T; Kuepfer, L; Lippert, J; Mueck, W; Sensse, A; Siegmund, HU; Weiss, W | 1 |
| Delbeck, M; Ellinghaus, P; Kast, R; Laux, V; Nickel, KF; Perzborn, E; Schäfer, S; Schermuly, RT; Strassburger, J; von Degenfeld, G | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Pan, G; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE | 1 |
| del Zoppo, GJ; Eliasziw, M | 1 |
| Arya, R; Patel, JP; Roberts, LN | 1 |
| Mega, JL | 1 |
| Becker, RC; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, D | 1 |
| Di Pasquale, G; Riva, L | 1 |
| Jolobe, OM | 1 |
| Niessner, A | 1 |
| Rose, A | 1 |
| Parra, D; Rosenstein, R | 1 |
| Pearson, S; Richards, AM; Troughton, R | 1 |
| Büller, HR; Combe, S | 1 |
| Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C | 1 |
| Abu-Fadel, MS; Dib, C; Golwala, H; Tafur, A | 1 |
| Parma, Z; Syzdół, M; Tendera, M | 1 |
| Alpert, JS | 1 |
| Lip, GY; Riva, N | 1 |
| Banerjee, A; Das, D; Guha, S; Hauli, I; Lohar, S; Matalobos, JS; Mukherjee, SK; Sahana, A | 1 |
| Khemasuwan, D; Suramaethakul, N | 1 |
| Gorelick, PB | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Carolei, A; Diener, HC; Donnan, GA; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Mas, JL; Massaro, A; Nessel, CC; Norrving, B; Paolini, JF; Patel, MR; Roine, RO; Singer, DE; Stevens, SR; Wong, L | 1 |
| Bryer, A | 1 |
| Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D | 2 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A | 1 |
| Bommer, WJ | 1 |
| Mustonen, P; Puurunen, M | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Schulman, S | 3 |
| Anglade, MW; Coleman, CI; Kluger, J; Lee, S; Pham, D; Pisacane, R | 1 |
| Goto, S; Hori, M; Iwamoto, K; Izumi, T; Kajikawa, M; Kato, M; Koretsune, Y; Matsumoto, M; Momomura, S; Tajiri, M; Tanahashi, N; Uchiyama, S; Ueda, H | 3 |
| Firriolo, FJ; Hupp, WS | 1 |
| Ismael, AG; Ribowsky, JH | 1 |
| Licina, MM; Lip, GY; Polovina, MM; Potpara, TS; Prostran, MS; Stojanovic, RM | 1 |
| Chongchivivat, A; Dakanali, M; Do, TH; Guizzunti, G; Haidekker, MA; Horn, A; Jarusreni, T; Lichlyter, D; Theodorakis, EA | 1 |
| Bhatt, DL; Kar, S | 1 |
| Callahan, S; Goldsberry, A; Kim, G; Yoo, S | 1 |
| Ansell, J; Mantha, S | 1 |
| Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S | 1 |
| Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY | 1 |
| Finsterer, J; Stöllberger, C | 2 |
| Capucci, A; Prisco, D | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Mangiafico, M; Mangiafico, RA | 1 |
| Zhang, S | 1 |
| Yasaka, M | 1 |
| Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH | 1 |
| Ahrens, I; Bode, C | 1 |
| Griffiths, M; Scully, C | 1 |
| Jin, M; Kamrul, R; Kosar, L; Schuster, B | 1 |
| Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV | 1 |
| Ahmad, Y; Lip, GY | 2 |
| Kopecky, S | 1 |
| Brenner, B; Hoffman, R | 1 |
| Giorgi, MA; Miguel, LS | 1 |
| Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG | 1 |
| Eikelboom, JW; Manolakos, JJ; Paikin, JS | 1 |
| Becker, RC; Chan, MY; Cyr, D; Kajikawa, M; Lin, M; Lucas, J; Moseley, A; Ortel, TL; Thompson, JW; Ueda, H | 1 |
| Gonzalez, MD; Naccarelli, GV | 1 |
| Sanaei, O | 1 |
| Wenger, NK | 1 |
| Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K | 1 |
| McBane, RD; Tafur, A; Wysokinski, WE | 1 |
| Merli, GJ | 1 |
| Valle Bernad, R | 1 |
| Blanco-Molina, A | 1 |
| Lipták, J | 1 |
| Graungaard, T; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Hannan, T; Khalafallah, AA; Renu, S; Sharp, C | 1 |
| Okada, Y; Yasaka, M | 1 |
| Fitchett, DH | 1 |
| Wooten, JM | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Chang, Y; Fox, KA; Go, AS; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 1 |
| Martin, EN; Money, SR; Shamoun, FE | 1 |
| Gross, PL; Weitz, JI | 1 |
| Kiss, RG | 1 |
| Mazur-Bialy, AI; Undas, A; Wypasek, E; Zdebska, K | 1 |
| Deitelzweig, SB | 1 |
| Greenspon, AJ | 1 |
| Brem, E; Foran, M; Koyfman, A | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Mohanty, S; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Zhang, Z | 1 |
| Reynolds, MR | 1 |
| Barrios, V; Escobar, C | 1 |
| Douketis, JD; Faraoni, D; Levy, JH; Samama, CM; Spring, JL | 1 |
| Dyrkorn, R; Roland, PD | 1 |
| Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S | 1 |
| Akwaa, F; Spyropoulos, AC | 1 |
| Galanis, T; Merli, GJ | 1 |
| Berman, JP; Halperin, JL | 1 |
| Lenchus, JD | 1 |
| Apostolakis, S; Kasmeridis, C; Lip, GY | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Pan, G; Patel, MR; Piccini, JP; Singer, DE | 1 |
| Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE | 1 |
| Jeffery, SM; Ogbonna, KC | 1 |
| Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C | 1 |
| Borges, F; Kachler, S; Klotz, KN; Matos, MJ; Santana, L; Uriarte, E; Vazquez-Rodriguez, S | 1 |
| Limdi, NA; Thigpen, JL | 1 |
| Hughes, DA; Pink, J; Pirmohamed, M | 1 |
| Kalus, JS | 1 |
| Spyropoulos, AC; Turpie, AG | 1 |
| Kerr, R; Ogden, G; Sime, G | 1 |
| Bonnabry, P; Daali, Y; Dayer, P; Desmeules, JA; Gschwind, L; Rollason, V | 1 |
| Aisenberg, J; Desai, J; Kolb, JM; Weitz, JI | 1 |
| Bauer, KA | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Singer, DE; van Diepen, S | 1 |
| Klein, HH | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hannan, KL; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Schwabe, K; Singer, DE | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; White, HD; Wojdyla, D | 1 |
| Pollack, CV | 1 |
| Gong, IY; Kim, RB | 1 |
| Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA | 1 |
| Boos, CJ; Camm, AJ; Nam, M | 1 |
| Diener, HC | 1 |
| Bates, P; Culpan, P; El-Daly, I; Reidy, J | 1 |
| Lopes, RD; Newby, LK; Truffa, AA | 1 |
| Lee, R; Lee, T | 1 |
| Rider, EB; Rider, OJ | 1 |
| Bhimani, AA; Hong, M | 1 |
| Opolonskaia, NA; Tseluĭko, VI; Vashakidze, ZS | 1 |
| Kamal, AK; Kamran, SH; Muzammil, SM | 1 |
| Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M | 1 |
| Delgado-Fernández, M | 1 |
| Hori, M; Kajikawa, M | 1 |
| Harrison, C | 1 |
| Dalen, JE | 1 |
| Fanikos, J | 1 |
| Li, C; Li, T; Mao, L; Yuan, K | 1 |
| Avorn, J | 1 |
| Ansell, J; Shameem, R | 1 |
| Diener, HC; Easton, JD; Hankey, GJ; Hart, RG | 1 |
| Agnelli, G; Becattini, C; Franco, L | 1 |
| den Exter, PL; Huisman, MV; Kooiman, J; van der Hulle, T | 1 |
| Eriksson, BI; Quinlan, DJ | 1 |
| Cohen, AA; Rider, T | 1 |
| Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW | 1 |
| Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y | 1 |
| Goto, S; Hori, M; Iekushi, K; Izumi, T; Kajikawa, M; Kato, M; Koretsune, Y; Matsumoto, M; Momomura, S; Tajiri, M; Tanahashi, N; Uchiyama, S; Ueda, H; Yamanaka, S | 3 |
| Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W | 1 |
| Asukai, Y; De Ruyck, M; Evers, T; Faes, P; Goethals, M; Kleintjens, J; Li, X; Rietzschel, ER; Saka, Ö; Simoens, S; Thijs, V; Vansieleghem, S | 1 |
| He, B; Kun, L; Liu, X; Wu, B | 1 |
| Azuma, S; Lum, CJ | 1 |
| Hughes, DA; Lane, S; Pink, J; Pirmohamed, M | 1 |
| Gunalingam, B; Markus, R; Spina, R; Subbiah, R | 1 |
| Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD | 1 |
| Kornej, J; Lip, GY; Potpara, T | 1 |
| Anisimova, AV; Borisov, SN; Gendlin, GE | 1 |
| Barbar, S; Milan, M; Pesavento, R; Prandoni, P; Vedovetto, V | 1 |
| Chandler, WL | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD | 1 |
| Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C | 1 |
| Ragni, MV; Seaman, CD; Smith, KJ | 1 |
| Banken, L; Jamois, C; Sanwald-Ducray, P | 1 |
| Avorn, J; Brennan, TA; Canestaro, WJ; Choudhry, NK; Ito, K; Matlin, OS; Patrick, AR; Shrank, WH | 1 |
| Germain, G; Laliberté, F; Lefebvre, P; Nelson, WW; Olson, WH; Pilon, D; Raut, MK; Schein, JR | 3 |
| Manning, JA | 1 |
| Giugliano, RP; Murphy, SA | 1 |
| Kitazono, T | 1 |
| Uchiyama, S | 1 |
| Laffan, M; Shapiro, S | 1 |
| Breithardt, G; Califf, RM; Fox, KA; Halperin, J; Hankey, GJ; Hellkamp, AS; Jones, WS; Mahaffey, KW; Patel, MR; Piccini, JP; Singer, DE | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Sherwood, MW; Singer, DE; White, HD; Wojdyla, DM | 1 |
| Bajorek, B; Wang, Y | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Du, EX; Li, N; Liu, Y; Tan, R; Wu, C; Wu, EQ; Xie, J | 1 |
| Giugliano, RP; Gonzalez-Quesada, CJ | 1 |
| Becka, M; Krätzschmar, J; Kubitza, D; Mück, W | 1 |
| Becker, RC; Califf, RM; Douketis, JD; Fox, KA; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Sherwood, MW; Singer, DE; Spyropoulos, AC | 1 |
| Crowther, M; Pasierski, T; Undas, A; Windyga, J | 1 |
| Iavelov, IS | 1 |
| Badhwar, N; Gerstenfeld, EP; Lee, BK; Lee, RJ; Marcus, GM; Olgin, J; Scheinman, M; Stepanyan, G; Tseng, ZH; Vedantham, V | 1 |
| Cloutier, M; Coleman, CI; Damaraju, CV; Laliberté, F; Lefebvre, P; Nelson, WW; Olson, WH; Pilon, D; Schein, JR | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE | 1 |
| Bouzin, C; Draoui, N; Feron, O; Riant, O; Schicke, O; Seront, E; Sonveaux, P | 1 |
| Thachil, J | 1 |
| Hagen, G; Klemp, M; Wisløff, T | 1 |
| Piccini, JP; Steinberg, BA | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Harrell, FE; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, R; Fox, KA; Hacke, W; Hankey, GJ; Hu, DY; Mahaffey, KW; Oomman, A; Patel, MR; Singer, DE; Tan, RS; Wong, KS | 1 |
| Bookhart, B; Huynh, L; Lefebvre, P; Mody, SH; Tran, KN; Zhuo, DY | 1 |
| Corrada, E; Ferri, M; Savonitto, S | 1 |
| Davidson, N; Galloway, SW; Lai, A; Thachil, J | 1 |
| Brieger, D | 1 |
| Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T | 1 |
| Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM | 1 |
| Hürlimann, D; Noll, G; Noll, S | 1 |
| Freedman, JE; Gersh, BJ | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, DM | 1 |
| Coleman, CI; Damaraju, CV; Nelson, WW; Schein, JR; Smith, DM; Song, X; Thomson, E | 1 |
| Hess, T; Konturek, P | 1 |
| Baker, WL; Chamberlin, KW | 1 |
| Dan, GA; Kaski, JC; Martínez-Rubio, A | 1 |
| Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P | 1 |
| Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A | 1 |
| Cappato, R; Davies, DW; Fields, LE; Hess, S; Hohnloser, SH; Ma, C; Marchlinski, FE; Naccarelli, GV; Natale, A; Wilber, DJ; Xiang, J | 1 |
| Askonen, K; Halinen, M; Huikuri, H; Koistinen, J; Parikka, H; Puurunen, M; Raatikainen, P; Virtanen, V | 1 |
| Piazza, G | 1 |
| Baba, Y; Hagii, J; Hitomi, H; Iwata, M; Kamada, T; Matsumoto, S; Metoki, N; Okumura, K; Osanai, T; Saito, S; Sasaki, S; Seino, S; Shiroto, H; Takahashi, K; Tomita, H; Uchizawa, T; Yasujima, M | 1 |
| Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P | 1 |
| Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA | 1 |
| Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE | 1 |
| Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N | 1 |
| Guo, X; Li, L; Tang, B; Xu, G; Zhang, Y; Zhou, X | 1 |
| Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH | 1 |
| Baumgartner, H; Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 1 |
| Dupree, LH; Reddy, P | 1 |
| Brueckmann, M; Clemens, A; Konstantinides, S; Lip, GY; Noack, H; Strack, A | 1 |
| Rudakova, AV; Tatarskiĭ, BA | 1 |
| Carroll, VS; Frei, J | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Steinberg, BA | 1 |
| Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Basavaraja, J; Inamdar, SR; Suresh Kumar, HM | 1 |
| Giugliano, RP; Plitt, A | 1 |
| Barnes, GD; Eagle, KA; Froehlich, JB | 1 |
| Madhusudhana, S; Qasem, A; Strasser, KM | 1 |
| Kadauke, S; Khor, B; Van Cott, EM | 1 |
| Kovács, T | 1 |
| Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F | 1 |
| de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI | 1 |
| Ezekowitz, MD; Kent, AP | 1 |
| Hohnloser, SH; Lopes, RD | 1 |
| Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR | 1 |
| Bernard, A; Devineni, D; Mamidi, RN; Manitpisitkul, P; Rothenberg, P; Sha, S; Skee, D; Stieltjes, H; Tian, H; Vaccaro, N; Weiner, S | 1 |
| Mima, Y; Nagata, S; Okada, Y; Sangatsuda, Y; Wakugawa, Y; Yasaka, M | 1 |
| Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R | 1 |
| Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 1 |
| Rondina, M | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Cairns, JA; Weitz, JI | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD | 1 |
| Arachchillage, DR; Cohen, H; Efthymiou, M; Lawrie, AS; Machin, SJ; Mackie, IJ | 1 |
| Cunningham, BT; Hergenrother, PJ; Peh, J | 1 |
| Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wettermark, B | 1 |
| Arepally, GM; Ortel, TL | 1 |
| Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB | 1 |
| Merli, GJ; Weitz, HH | 1 |
| Crighton, A; Gibson, J; Scott, A | 1 |
| Loh, JB; Ng, HJ; Sum, CL; Than, H | 1 |
| Bultas, J | 1 |
| Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH | 1 |
| Oberhofer, E | 1 |
| Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; Washam, JB | 1 |
| Fukae, S; Izumida, S; Kawano, H; Kohno, Y; Koide, Y; Maemura, K; Takeno, M; Tsuneto, A | 1 |
| Hogg, K; Weitz, JI; Yeh, CH | 1 |
| Abraham, NS; Alexander, GC; Crown, W; Haas, LR; Heien, H; Shah, ND; Singh, S | 1 |
| Alexander, GC; Chang, HY; Singh, S; Tang, W; Zhou, M | 1 |
| Rose, A; Vaughan Sarrazin, MS | 1 |
| Gehrie, E; Tormey, C | 1 |
| Phillips, R | 1 |
| Jiang, D; Koong, AC; Niwa, M | 1 |
| Lythgoe, M | 1 |
| Lewis, LS | 1 |
| Botto, GL; Colonna, P; Troccoli, R | 1 |
| Feng, W; Lin, Y; Lu, H; Xi, AM; Yan, CZ; Zhang, Y | 1 |
| Megally Abdo, NY; Mohareb, RM | 1 |
| Koretz, RL | 1 |
| Fox, KA; Hellkamp, AS; Patel, MR | 2 |
| Lasek-Bal, A; Piekarski, M; Puz, P; Urbanek, T | 1 |
| Powell, JR | 1 |
| Alam, S; Albratty, M; El-Sharkawy, KA | 1 |
| Hu, Y; Huang, S; Tang, L | 1 |
| Abdallah, AEM; Mohamed, AA; Mohareb, RM | 1 |
| Cai, G; Guo, J; Kong, L; Ren, Y; Song, D; Yu, W; Zhang, W; Zhu, J | 1 |
| Abdo, NYM; Ibrahim, RA; Mohareb, RM; Samir, EM | 1 |
| Alanazi, MM; Amran, SI; Biswas, S; Chander, S; Das, B; Hadda, TB; Hasan, AH; Jamalis, J; Murugesan, S; Pratama, MRF; Shakya, S | 1 |
116 review(s) available for thiophenes and warfarin
| Article | Year |
|---|---|
Beyond unfractionated heparin and warfarin: current and future advances.
Topics: Angina, Unstable; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Brain Ischemia; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Forecasting; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Morpholines; Myocardial Infarction; Peptide Fragments; Polysaccharides; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Thrombosis; Warfarin | 2007 |
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.
Topics: Anesthesia, Conduction; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Azetidines; Benzylamines; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin | 2008 |
Rivaroxaban, an oral direct factor Xa inhibitor.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Animals; Anticoagulants; Atrial Fibrillation; Binding Sites; Clinical Trials as Topic; Comorbidity; Drug Evaluation, Preclinical; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Rats; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin | 2008 |
[Rivaroxaban: mode of action].
Topics: Administration, Oral; Anticoagulants; Clinical Trials as Topic; Drug Administration Schedule; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Molecular Structure; Morpholines; Postoperative Complications; Preanesthetic Medication; Prothrombin Time; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2008 |
Old versus new anticoagulants: focus on pharmacology.
Topics: Animals; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Oligosaccharides; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Warfarin | 2010 |
VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
Topics: Anticoagulants; Aspirin; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2010 |
Implementing genotype-guided antithrombotic therapy.
Topics: Anticoagulants; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Genetic Privacy; Genotype; Health Policy; Humans; Mixed Function Oxygenases; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine; Vitamin K Epoxide Reductases; Warfarin | 2010 |
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2010 |
New antithrombotic agents--insights from clinical trials.
Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine | 2010 |
The need for novel anticoagulation therapy in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Cyclic N-Oxides; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; Morpholines; Naphthalenes; Polysaccharides; Propionates; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Triple therapy in hospitalized patients: facts and controversies.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hospitalization; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin | 2011 |
Triple therapy: boon or bane for high-risk CV patients?
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Warfarin | 2011 |
New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Morpholines; Outpatients; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism; Warfarin | 2011 |
Anticoagulating obese patients in the modern era.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Multicenter Studies as Topic; Obesity; Polysaccharides; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Venous Thrombosis; Warfarin | 2011 |
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2011 |
A new era of antithrombotic therapy in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Drugs, Investigational; Factor X; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Antithrombin Proteins; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Chemoprevention; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
Treatment of venous thromboembolism with dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
The management of antithrombotic medication in skin surgery.
Topics: Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Rivaroxaban; Thienopyridines; Thiophenes; Vitamin K; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Benzoates; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Warfarin | 2012 |
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drug Approval; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
The promise of novel direct oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Warfarin | 2012 |
Advances in the management of venous thromboembolism.
Topics: Anticoagulants; Antithrombins; Clinical Trials as Topic; Diagnostic Imaging; Disease Management; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Radiography; Risk; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism; Venous Thrombosis; Vitamin K; Warfarin | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2012 |
Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
Topics: Anticoagulants; Atrial Fibrillation; Gastrointestinal Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
What's new in antiplatelet and anticoagulant therapy recommendations for unstable angina/non-ST-elevation myocardial infarction: 2012 focused update from the American College of Cardiology Foundation/American Heart Association task force on practice guide
Topics: Adenosine; Administration, Oral; Angina, Unstable; Anticoagulants; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Treatment Outcome; Warfarin | 2012 |
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
Potential role of rivaroxaban in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Dose-Response Relationship, Drug; Hemorrhage; Humans; Intracranial Hemorrhages; Morpholines; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
Comparing new anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants: which one should my patient use?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hematology; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Warfarin | 2012 |
[Novel agents for antithrombotic therapy in cardiology].
Topics: Adenosine; Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2012 |
A review of oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Medication Adherence; Morpholines; Renal Insufficiency; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin | 2013 |
Managing new oral anticoagulants in the perioperative and intensive care unit setting.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Critical Care; Dabigatran; Hemorrhage; Humans; Intensive Care Units; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2013 |
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2013 |
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Comorbidity; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyridines; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2013 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Reversal of oral anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Managing bleeding in anticoagulated patients in the emergency care setting.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Hemorrhage; Hemostasis; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Polymorphism, Genetic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin | 2014 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparinux; Fractures, Bone; Heparin; Humans; Mass Screening; Morpholines; Multiple Trauma; Pelvis; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Vena Cava Filters; Venous Thromboembolism | 2013 |
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2013 |
The changing face of oral anticoagulants.
Topics: Anticoagulants; Antithrombin Proteins; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Prodrugs; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2013 |
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pakistan; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Disadvantages of VKA and requirements for novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants in elderly patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Dosage Calculations; Humans; Morpholines; Pharmacogenetics; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin | 2013 |
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[Prevention of stroke in patients with atrial fibrillation: a role of modern anticoagulants].
Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Fondaparinux; Humans; Male; Morpholines; Obesity; Polysaccharides; Postthrombotic Syndrome; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Sex Factors; Thiophenes; Thrombophilia; Ultrasonography; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2014 |
Outpatient management of oral anticoagulation in atrial fibrillation.
Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
[Evidence of novel oral anticoagulants (NOAC)].
Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Infarction; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
[Prevention of embolic heart complications in atrial fibrillation: possibilities of using rivaroxaban].
Topics: Anticoagulants; Atrial Fibrillation; Controlled Clinical Trials as Topic; Embolism; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Embolism; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin | 2014 |
Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
[Update on current care guideline: atrial fibrillation].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Incidence; Morpholines; Practice Guidelines as Topic; Prevalence; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Oral anticoagulants: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; Kidney Function Tests; Morpholines; Perioperative Period; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Switching between oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin | 2014 |
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Prescriptions; Drug Utilization; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2015 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Laboratories; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Targeting the IRE1α-XBP1 branch of the unfolded protein response in human diseases.
Topics: Aldehydes; Animals; Apoptosis; Cell Survival; Coumarins; Disease Models, Animal; Disease Progression; DNA-Binding Proteins; Drug Design; Drug Discovery; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Endoribonucleases; Homeostasis; Humans; Mice; Neoplasms; Neurodegenerative Diseases; Prognosis; Protein Folding; Protein Serine-Threonine Kinases; Quercetin; Regulatory Factor X Transcription Factors; Signal Transduction; Sulfonamides; Thiophenes; Toyocamycin; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1 | 2015 |
39 trial(s) available for thiophenes and warfarin
| Article | Year |
|---|---|
Eprosartan does not affect the pharmacodynamics of warfarin.
Topics: Acrylates; Adult; Anticoagulants; Antihypertensive Agents; Double-Blind Method; Drug Interactions; Humans; Imidazoles; International Normalized Ratio; Male; Middle Aged; Thiophenes; Warfarin | 1998 |
Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects.
Topics: Adult; Anticoagulants; Blood Coagulation Tests; Drug Interactions; Duloxetine Hydrochloride; Female; Humans; Isomerism; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Statistics as Topic; Thiophenes; Warfarin; Young Adult | 2009 |
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Medical Records; Morpholines; Research Design; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2010 |
Rivaroxaban and false positive lupus anticoagulant testing.
Topics: Anticoagulants; Antiphospholipid Syndrome; Blood Coagulation; Blood Coagulation Tests; False Positive Reactions; Humans; Lupus Coagulation Inhibitor; Morpholines; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Vitamin K; Warfarin | 2010 |
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2011 |
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2011 |
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Humans; Intention to Treat Analysis; Ischemic Attack, Transient; Morpholines; Multicenter Studies as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Proteins; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Proteomics; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin | 2012 |
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K ant
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa; Female; Follow-Up Studies; Humans; Incidence; Male; Morpholines; Predictive Value of Tests; Reproducibility of Results; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Japan; Kidney; Male; Middle Aged; Morpholines; Renal Insufficiency; Reproducibility of Results; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention o
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Morpholines; Outcome Assessment, Health Care; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Time Factors; Warfarin; Withholding Treatment | 2013 |
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Electric Countershock; Female; Humans; Male; Middle Aged; Morpholines; Multicenter Studies as Topic; Multivariate Analysis; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
Topics: Aged; Anticoagulants; Asia; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Monitoring; Europe; Female; Healthcare Disparities; Humans; International Normalized Ratio; Linear Models; Male; Morpholines; Multivariate Analysis; North America; Predictive Value of Tests; Residence Characteristics; Rivaroxaban; South Africa; South America; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2013 |
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Heart Failure; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin | 2013 |
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Clinical Protocols; Continuity of Patient Care; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Embolism; Factor Xa; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Proportional Hazards Models; Research Design; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; China; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Primary Prevention; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2014 |
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial.
Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Disease-Free Survival; Double-Blind Method; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Morpholines; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2014 |
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2014 |
The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.
Topics: Anticoagulants; Area Under Curve; Cross-Over Studies; Drug Interactions; Factor VII; Humans; Male; Oxazoles; PPAR alpha; PPAR gamma; Prothrombin Time; Stereoisomerism; Thiophenes; Warfarin; Young Adult | 2014 |
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Humans; Male; Morpholines; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Pressure; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Vitamin K; Warfarin | 2014 |
Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial.
Topics: Aged; Asian People; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Hypertension; Japan; Male; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.
Topics: Adolescent; Adult; Anticoagulants; Blood Coagulation; Factor VIIa; Factor Xa; Healthy Volunteers; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Prothrombin; Prothrombin Time; Rivaroxaban; Thiophenes; Warfarin; Young Adult | 2014 |
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stro
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Intracranial Embolism; Male; Morpholines; Proportional Hazards Models; Prospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Blood Transfusion; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Plasma; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Risk Factors; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in at
Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Black People; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Morpholines; Prospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Monitoring; Embolism; Europe; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; North America; Point-of-Care Systems; Predictive Value of Tests; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2014 |
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Asia, Eastern; Asian People; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Patient Safety; Postoperative Care; Preoperative Care; Prospective Studies; Pulmonary Embolism; Rivaroxaban; Statistics, Nonparametric; Survival Rate; Thiophenes; Treatment Outcome; Venous Thrombosis; Vitamin K; Warfarin | 2014 |
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aortic Valve Insufficiency; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mitral Valve Insufficiency; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Morpholines; Prospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2015 |
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
Topics: Adult; Anticoagulants; Area Under Curve; Blood Coagulation; Canagliflozin; Cardiotonic Agents; Contraceptives, Oral, Combined; Cross-Over Studies; Digoxin; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Ethinyl Estradiol; Female; Glucosides; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; International Normalized Ratio; Levonorgestrel; Male; Metabolic Clearance Rate; Middle Aged; Polypharmacy; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Warfarin; Young Adult | 2015 |
184 other study(ies) available for thiophenes and warfarin
| Article | Year |
|---|---|
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
Ticrynafen effect on warfarin protein binding in human serum.
Topics: Adult; Blood Proteins; Diuretics; Drug Interactions; Glycolates; Humans; In Vitro Techniques; Male; Phenoxyacetates; Protein Binding; Thiophenes; Warfarin | 1979 |
Effects of suprofen, an inhibitor of prostaglandin biosynthesis, on platelet function, plasma coagulation and fibrinolysis II. In vivo experiments.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Coagulation; Blood Platelets; Collagen; Dogs; Fibrinolysis; Guinea Pigs; Hemostasis; Male; Phenylbutazone; Phenylpropionates; Platelet Adhesiveness; Platelet Aggregation; Prostaglandin Antagonists; Pyrimidines; Rats; Thiophenes; Time Factors; Warfarin | 1975 |
[Abnormalities of blood coagulation and effect of anticoagulant therapy in postoperative patients with lung cancer].
Topics: Adult; Aged; Anticoagulants; beta-Thromboglobulin; Blood Coagulation Disorders; Female; Humans; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Thiophenes; Ticlopidine; Warfarin | 1986 |
[Relation of conformation and antalgic activity of 2-aryl-dihydrothienocoumarins].
Topics: Analgesics; Chemical Phenomena; Chemistry; Coumarins; Magnetic Resonance Spectroscopy; Structure-Activity Relationship; Thiophenes; X-Ray Diffraction | 1988 |
Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis.
Topics: Animals; Aspirin; Blood Coagulation Disorders; Cattle; Collagen; Dogs; Hemorrhage; Hemostatic Techniques; Hemostatics; Heparin; Spleen; Thiophenes; Thrombocytopenia; Ticlopidine; Warfarin | 1986 |
[Antithrombogenic therapy based on the study of the changes in platelet aggregability and blood coagulability in the early period after prosthetic valve replacement].
Topics: Adult; Anticoagulants; Blood Coagulation; Dipyridamole; Female; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Male; Middle Aged; Platelet Aggregation; Postoperative Complications; Thiophenes; Thrombosis; Ticlopidine; Warfarin | 1985 |
Petite mutants induced in yeast by optical brighteners.
Topics: Amines; Benzoxazoles; Color; Coumarins; Cytoplasm; Darkness; Ethanol; Extrachromosomal Inheritance; Ketones; Mutation; Photochemistry; Photosensitivity Disorders; Quinolines; Saccharomyces cerevisiae; Stilbenes; Sulfonic Acids; Surface-Active Agents; Thiophenes; Triazines | 1971 |
[On an analog of dicumarol in the thiophene series, carrying carboxyl functions].
Topics: Animals; Chemical Phenomena; Chemistry; Coumarins; In Vitro Techniques; Rats; Thiophenes | 1965 |
Correlation between the antilipolytic and hypoglycemic actions of some salicylate structural congeners in normal and alloxan-diabetic rats.
Topics: Animals; Anti-Bacterial Agents; Benzoates; Blood Glucose; Coumarins; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Furans; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Metabolism; Nicotinic Acids; ortho-Aminobenzoates; Proline; Rats; Salicylates; Thiophenes | 1969 |
Photochemical and photobiological studies on methylthioangelicins.
Topics: Cell Division; Coumarins; Cross-Linking Reagents; DNA; DNA Adducts; Furocoumarins; HeLa Cells; Humans; Mass Spectrometry; Molecular Structure; Mutagenesis; Mutagens; Myoviridae; Photobiology; Photochemistry; Photolysis; Photosensitizing Agents; Reactive Oxygen Species; Salmonella typhimurium; Thiophenes | 1999 |
Thienocoumarin derivatives: interaction with nucleic acids and synthetic polydeoxyribonucleotides.
Topics: Animals; Cattle; Cell Division; Coumarins; DNA; DNA, Bacterial; HL-60 Cells; Humans; Kinetics; Methoxsalen; Photosensitizing Agents; Polydeoxyribonucleotides; Skin; Thiophenes; Tumor Cells, Cultured; Ultraviolet Rays | 2000 |
The reaction of digitoxin and digoxin with cyanoacetic acid hydrazide: synthesis of coumarin, thiazole, thiophene and pyridine derivatives with potential biological activities.
Topics: Coumarins; Digitoxin; Digoxin; Hydrazines; Indicators and Reagents; Magnetic Resonance Spectroscopy; Pyridines; Thiazoles; Thiophenes | 2001 |
Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio.
Topics: Adult; Anticoagulants; Antidepressive Agents; Drug Interactions; Duloxetine Hydrochloride; Female; Humans; International Normalized Ratio; Thiophenes; Warfarin | 2006 |
Development of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drug Delivery Systems; Drug Design; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Hemorrhage; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2007 |
A replacement for warfarin: the search continues.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase II as Topic; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin | 2007 |
Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity.
Topics: Alkylation; Anti-Asthmatic Agents; Binding, Competitive; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; Half-Life; Humans; Hydroxyurea; Ibuprofen; Models, Biological; Serum Albumin; Tandem Mass Spectrometry; Thiophenes; Warfarin | 2007 |
New issues in oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clinical Trials as Topic; Cytochrome P-450 CYP2C9; Dabigatran; Enoxaparin; Genetic Variation; Humans; Mixed Function Oxygenases; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyridines; Rivaroxaban; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2008 |
Comparison of citrus coumarins on carcinogen-detoxifying enzymes in Nrf2 knockout mice.
Topics: Animals; Anticarcinogenic Agents; Antioxidants; Basic-Leucine Zipper Transcription Factors; Cell Line, Tumor; Citrus; Coumarins; Cytosol; Female; Glutathione Transferase; Green Fluorescent Proteins; Humans; Liver; Male; Mice; Mice, Knockout; NAD(P)H Dehydrogenase (Quinone); NADPH Dehydrogenase; Pyrazines; Response Elements; Thiones; Thiophenes; Transfection | 2009 |
Enantiospecific binding of Rotigotine and its antipode to serum albumins: Investigation of binding constants and binding sites by partial-filling ACE.
Topics: Animals; Binding, Competitive; Electrophoresis, Capillary; Humans; Kinetics; Linear Models; Pilot Projects; Serum Albumin; Serum Albumin, Bovine; Stereoisomerism; Tetrahydronaphthalenes; Thiophenes; Warfarin | 2009 |
Cardiovascular disease gets personal.
Topics: Anticoagulants; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Female; Genetic Predisposition to Disease; Genetic Testing; Genetic Variation; Genome-Wide Association Study; Genomics; Humans; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin | 2009 |
[Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians].
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Benzimidazoles; Blood Loss, Surgical; Cesarean Section; Contraindications; Dabigatran; Europe; Evidence-Based Medicine; Female; Fetus; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; Morpholines; Polysaccharides; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Hematologic; Puerperal Disorders; Pyridines; Rivaroxaban; Societies, Medical; Thiophenes; Thrombophilia; United States; Uterine Hemorrhage; Venous Thromboembolism; Warfarin | 2009 |
Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Blood Coagulation Disorders; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2010 |
[Anticoagulant therapy in cardiology: yesterday, today, tomorrow].
Topics: Anticoagulants; Benzimidazoles; Carboxypeptidase B2; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Receptor, PAR-1; Rivaroxaban; Thiophenes; Thrombin; Thrombomodulin; Thrombosis; Treatment Outcome; Warfarin | 2010 |
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Safety; Secondary Prevention; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2010 |
Novel synthesis of hydrazide-hydrazone derivatives and their utilization in the synthesis of coumarin, pyridine, thiazole and thiophene derivatives with antitumor activity.
Topics: Antineoplastic Agents; Azides; Cell Division; Cell Line, Tumor; Coumarins; Drug Screening Assays, Antitumor; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Pyridines; Thiazoles; Thiophenes | 2010 |
New alternative to warfarin may help reduce stroke risk in patients with AF.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Drug Approval; Humans; Morpholines; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2011 |
Detection of liposome membrane viscosity perturbations with ratiometric molecular rotors.
Topics: 1-Propanol; Calibration; Coumarins; Fluorescent Dyes; Humans; Liposomes; Molecular Conformation; Phosphatidylcholines; Sensitivity and Specificity; Spectrometry, Fluorescence; Thiophenes; Viscosity | 2011 |
Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Circulation; Blood Coagulation; Computer Simulation; Enoxaparin; Humans; Models, Biological; Morpholines; Naphthalenes; Partial Thromboplastin Time; Propionates; Rivaroxaban; Thiophenes; Translational Research, Biomedical; Treatment Outcome; Warfarin | 2011 |
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
Topics: Animals; Blood Coagulation; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Familial Primary Pulmonary Hypertension; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Morpholines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2011 |
New options in anticoagulation for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intention to Treat Analysis; Intracranial Hemorrhages; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2011 |
A new era for anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2011 |
FDA advisory decision highlights some problems inherent in pragmatic trials.
Topics: Advisory Committees; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Approval; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; United States Food and Drug Administration; Warfarin | 2011 |
Lack of an antagonist to reverse the action of dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin | 2011 |
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin | 2011 |
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin | 2011 |
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin | 2011 |
[New treatments for venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thrombosis; Warfarin | 2011 |
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dabigatran; Decision Making, Computer-Assisted; Denmark; Humans; Intracranial Hemorrhages; Morpholines; Population Groups; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different?
Topics: Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Drug Approval; Drug Interactions; Food-Drug Interactions; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
New directions in anticoagulation.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Thiophene anchored coumarin derivative as a turn-on fluorescent probe for Cr3+: cell imaging and speciation studies.
Topics: Cells; Chromium; Coumarins; Crystallography, X-Ray; Cytological Techniques; Diagnostic Imaging; Fluorescent Dyes; Molecular Structure; Thiophenes | 2012 |
Rivaroxaban and recurrent stroke prevention in AF.
Topics: Anticoagulants; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New antithrombotic drugs: a revolution in stroke management.
Topics: Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Approval; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Monitoring, Physiologic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Finland; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Control; Dabigatran; Endpoint Determination; Health Expenditures; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; Warfarin | 2012 |
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Markov Chains; Medicare; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2012 |
Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Humans; Morpholines; Narcotics; Oral Hemorrhage; Oral Surgical Procedures; Postoperative Hemorrhage; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Oral anticoagulants for atrial fibrillation: Which one to choose?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Costs; Drug Substitution; Humans; Morpholines; Pyridines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Self-calibrating viscosity probes: design and subcellular localization.
Topics: Calibration; Cell Line, Tumor; Cell Membrane; Coumarins; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Microscopy, Confocal; Thiophenes; Viscosity | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA?
Topics: Anticoagulants; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Morpholines; Stroke; Thiophenes; Warfarin | 2012 |
[The ROCKET AF study].
Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
J-ROCKET AF trial increased expectation of lower-dose rivaroxaban made for Japan.
Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Rivaroxaban in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2012 |
Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; United States; Warfarin | 2013 |
How big is the impact of the warfarin cost on the cost-effectiveness of rivaroxoban for stroke prevention in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Stroke; Thiophenes; Warfarin | 2012 |
Periprocedural anticoagulant management.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Morpholines; Neoplasms; Perioperative Care; Risk Assessment; Rivaroxaban; Stents; Thiophenes; Venous Thromboembolism; Warfarin | 2012 |
The new oral anticoagulants: a challenge for hospital formularies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Formularies, Hospital as Topic; Humans; Morpholines; Pennsylvania; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
[Rivaroxaban versus warfarin: results of the ROCKET study].
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Humans; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Morpholines; Pharmacovigilance; Primary Prevention; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2012 |
Extensive venous thrombosis in a healthy young man with a short inferior vena cava syndrome treated successfully with rivaroxaban.
Topics: Adult; Anticoagulants; Edema; Enoxaparin; Humans; Iliac Vein; Incidental Findings; Male; Morpholines; Rivaroxaban; Thiophenes; Tomography, X-Ray Computed; Travel; Vena Cava, Inferior; Venous Thrombosis; Warfarin; Young Adult | 2012 |
[Management of intracranial hemorrhage during anticoagulant therapy with warfarin or novel anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Humans; Intracranial Embolism; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants.
Topics: Administration, Oral; Adult; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Exons; Female; Genetic Predisposition to Disease; Genetic Testing; Genotype; Haplotypes; Hemorrhage; Humans; Hypertension; Mixed Function Oxygenases; Morpholines; Mutation; Poland; Rivaroxaban; Thiophenes; Vitamin K; Vitamin K Epoxide Reductases; Warfarin | 2013 |
Transitions of care in anticoagulation management for patients with atrial fibrillation.
Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Discontinuation of rivaroxaban: filling in the gaps.
Topics: Atrial Fibrillation; Blood Coagulation; Female; Humans; Male; Morpholines; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[New anticoagulants--should we have a little bit of cold water in the blood?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Humans; Markov Chains; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2013 |
Chalcone-based derivatives as new scaffolds for hA3 adenosine receptor antagonists.
Topics: Animals; Binding, Competitive; Chalcone; CHO Cells; Coumarins; Cricetinae; Cricetulus; Humans; Ligands; Purinergic P1 Receptor Antagonists; Radioligand Assay; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptor, Adenosine A3; Structure-Activity Relationship; Thiophenes | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Comorbidity; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Warfarin | 2013 |
Pharmacologic interventions for reversing the effects of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Loss, Surgical; Dabigatran; Drug Therapy, Combination; Emergencies; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1; Warfarin | 2013 |
Anticoagulant guidelines.
Topics: Anticoagulants; Benzimidazoles; Coumarins; Dabigatran; Dental Care for Chronically Ill; Hemostatic Techniques; Humans; Interprofessional Relations; Morpholines; Oral Hemorrhage; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyridines; Rivaroxaban; Thiophenes | 2013 |
Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model.
Topics: Acenocoumarol; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Humans; Microscopy, Electron, Transmission; Morpholines; Rivaroxaban; Thiophenes; Vitamin K; Warfarin | 2013 |
Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Ask the doctors. I have atrial fibrillation and have been taking warfarin to prevent blood clots for 10 years. It has not given me any problems. However, I do hate going to my doctor's office to get my INR blood test every month. I'm wondering whether
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Health Behavior; Humans; Morpholines; Pyrazoles; Pyridines; Thiophenes; Warfarin | 2013 |
[Comparison of the therapeutic effect of the Warfarin and Rivaroksaban among the patients with not-valuate fibrillation of atrium].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; United States; Warfarin | 2013 |
The J-ROCKET AF study: a matter of ethnicity or a matter of weight?
Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Warfarin | 2013 |
The J-ROCKET AF Study: a matter of ethnicity or a matter of weight? Reply.
Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Warfarin | 2013 |
Antibacterial drugs: hitting the tuberculosis wall.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Benzothiazoles; Coumarins; Female; Mycobacterium tuberculosis; Mycolic Acids; Polyketide Synthases; Thiophenes; Tuberculosis, Pulmonary | 2013 |
Should the newer oral anticoagulants be withheld from patients with valvular AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confounding Factors, Epidemiologic; Dabigatran; Decision Making; Evidence-Based Medicine; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pharmacoepidemiology; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
Topics: Anticoagulants; Atrial Fibrillation; Belgium; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Humans; Markov Chains; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Models, Economic; Morpholines; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Warfarin | 2014 |
A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
Topics: Aged, 80 and over; Anticoagulants; Arginine; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Glomerular Filtration Rate; Hawaii; Humans; Male; Morpholines; Pipecolic Acids; Retrospective Studies; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2013 |
Percutaneous left atrial appendage occlusion with a Watchman device following recurrent stroke on warfarin and rivaroxaban in patient with paroxysmal atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Anticoagulation without monitoring.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Humans; Morpholines; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2013 |
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Factor Xa Inhibitors; Health Care Costs; Humans; Italy; Markov Chains; Morpholines; Pyrazoles; Pyridones; Quality of Life; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
Topics: Anticoagulants; Cohort Studies; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Morpholines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism; Warfarin | 2013 |
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; United States; Warfarin | 2013 |
[Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy].
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Substitution; Factor Xa Inhibitors; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?
Topics: Aged; Anticoagulants; Atrial Fibrillation; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Atrial fibrillation and prior MI: searching for balance in ischaemic and bleeding events in patients treated with factor-specific anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2014 |
[How to properly use warfarin and new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Humans; International Normalized Ratio; Morpholines; Practice Guidelines as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
New oral anticoagulants: their role and future.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China.
Topics: Anticoagulants; China; Female; Health Care Costs; Heparin, Low-Molecular-Weight; Hospitalization; Humans; International Normalized Ratio; Logistic Models; Male; Middle Aged; Morpholines; Pulmonary Embolism; Retrospective Studies; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Veins; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin; Young Adult | 2014 |
Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux.
Topics: Animals; Breast Neoplasms; Colorectal Neoplasms; Coumarins; Female; HCT116 Cells; Humans; Lactic Acid; MCF-7 Cells; Mice; Neoplasm Recurrence, Local; Prognosis; Thiophenes; Uracil | 2014 |
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Humans; Markov Chains; Models, Statistical; Morpholines; Norway; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Databases, Factual; Female; Hospital Costs; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Morpholines; Propensity Score; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin; Young Adult | 2014 |
A cost-analysis model for anticoagulant treatment in the hospital setting.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Factor Xa Inhibitors; Humans; Inpatients; Length of Stay; Models, Economic; Morpholines; Pulmonary Embolism; Randomized Controlled Trials as Topic; Retrospective Studies; Rivaroxaban; Thiophenes; United States; Venous Thrombosis; Warfarin | 2014 |
Fatal bleedings with prasugrel as part of triple antithrombotic therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Arteriovenous Malformations; Aspirin; Drug Therapy, Combination; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Warfarin | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Atrial fibrillation and stroke prevention in aging patients: what's good can be even better.
Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Databases, Factual; Female; Humans; Male; Medication Adherence; Middle Aged; Morpholines; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2014 |
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP2C9; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2014 |
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Thrombophilia testing, recurrent thrombosis, and women's health.
Topics: Adult; Aged; Anticoagulants; Female; Humans; Male; Mass Screening; Morpholines; Mutation; Prothrombin; Recurrence; Risk Factors; Rivaroxaban; Thiophenes; Thrombophilia; Treatment Outcome; Venous Thrombosis; Warfarin; Women's Health | 2014 |
Atrial fibrillation choices. Picking an anti-clotting drug.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Anticlotting therapy for atrial fibrillation: should you stay with the devil you know? Preventing stroke with warfarin (Coumadin) can be tricky. New anticlotting drugs can help if you accept certain trade-offs--and take them exactly as directed.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Female; Fibrinolytic Agents; Humans; Male; Morpholines; Patient Education as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2014 |
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Combined Modality Therapy; Dabigatran; Female; Heparin; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Radio Waves; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comorbidity; Diabetes Mellitus; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Hypertension; Incidence; Inpatients; Male; Morpholines; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability.
Topics: Administration, Oral; Adolescent; Anticoagulants; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Morpholines; Nephrotic Syndrome; Pulmonary Embolism; Rivaroxaban; Thiophenes; Thrombophilia; Venous Thromboembolism; Warfarin | 2014 |
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Early Detection of Cancer; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Incidence; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes; Warfarin | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin | 2014 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2015 |
Solvents effect on the absorption and fluorescence spectra of 7-diethylamino-3-thenoylcoumarin: evaluation and correlation between solvatochromism and solvent polarity parameters.
Topics: Coloring Agents; Coumarins; Solvents; Spectrometry, Fluorescence; Thiophenes | 2015 |
Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Length of Stay; Male; Middle Aged; Morpholines; Retrospective Studies; Rivaroxaban; Socioeconomic Factors; Stroke; Thiophenes; Warfarin | 2014 |
Activated protein C resistance testing for factor V Leiden.
Topics: Activated Protein C Resistance; Adult; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation Tests; Child; Dabigatran; Factor V; Factor Xa; False Positive Reactions; Female; Hirudins; Humans; Lupus Coagulation Inhibitor; Morpholines; Peptide Fragments; Pipecolic Acids; Pregnancy; Protein C; Recombinant Proteins; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2014 |
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Coumarins; Dabigatran; Humans; Markov Chains; Middle Aged; Morpholines; Netherlands; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United Kingdom | 2014 |
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin | 2014 |
Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention.
Topics: Anticoagulants; Aortic Valve Insufficiency; Atrial Fibrillation; Female; Humans; Male; Mitral Valve Insufficiency; Morpholines; Thiophenes; Warfarin | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism | 2014 |
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Acute thrombocytopenia after initiating anticoagulation with rivaroxaban.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Humans; Intracranial Hemorrhages; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombocytopenia; Warfarin | 2014 |
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
ACP Journal Club: in nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age.
Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2015 |
Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
Detection of protein-small molecule binding using a self-referencing external cavity laser biosensor.
Topics: Biosensing Techniques; Carbonic Anhydrase II; Enzymes, Immobilized; Humans; Indoles; Lasers; Protein Binding; Serum Albumin; Small Molecule Libraries; Sulfonamides; Thiophenes; Warfarin | 2014 |
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
Web Exclusives. The consult guys--too close for comfort? For how long must I stop this anticoagulant for an epidural?
Topics: Adrenal Cortex Hormones; Aged; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Humans; Injections, Epidural; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin; Withholding Treatment | 2015 |
Novel anticoagulants make life easier for patients with atrial fibrillation. The new drugs have many advantages over Coumadin--but they aren't perfect--and they have no antidotes in case of overdose.
Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
The management of dental patients taking new generation oral anticoagulants.
Topics: Anesthetics, Local; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dental Care for Chronically Ill; Drug Interactions; Factor Xa Inhibitors; Hemostatic Techniques; Humans; Morpholines; Oral Surgical Procedures; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report.
Topics: Administration, Oral; Blood Coagulation; Drug Monitoring; Factor Xa Inhibitors; Female; Heparin; Humans; International Normalized Ratio; Middle Aged; Morpholines; Predictive Value of Tests; Prothrombin Time; Reproducibility of Results; Rivaroxaban; Thiophenes; Thrombocytopenia; Time Factors; Treatment Outcome; Warfarin | 2015 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-Life; Hemorrhage; Humans; Kidney Function Tests; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Death, Sudden; Diabetes Mellitus; Digoxin; Factor Xa Inhibitors; Female; Heart Failure; Heart Rate; Humans; Intracranial Embolism; Male; Morpholines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Rivaroxaban; Sex Distribution; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
Rivaroxaban therapy resulting in the resolution of right atrial thrombosis resistant to ordinary control with warfarin in a patient with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Thrombosis; Factor Xa Inhibitors; Heart Atria; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2015 |
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Medicaid; Middle Aged; Morpholines; Patient Selection; Practice Patterns, Physicians'; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Observational Studies as Topic; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
Safety of new oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin | 2015 |
Anticoagulation therapy: Bleeding no worse with novel agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin | 2015 |
Effective antidotes for new anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin | 2015 |
Meta-analysis should not be subject to selectivity and imbalance.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin | 2015 |
[The X-VeRT study].
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Embolism; Factor Xa Inhibitors; Heart Diseases; Hemorrhage; Humans; International Normalized Ratio; Middle Aged; Morpholines; Multicenter Studies as Topic; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Risk; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2015 |
[The changes of vascular active substances in pulmonary embolism rats and a comparative study of anticoagulant drugs].
Topics: Animals; Anticoagulants; Disease Models, Animal; Endothelin-1; Heparin, Low-Molecular-Weight; Hypertension, Pulmonary; Lung; Morpholines; Pulmonary Embolism; Rats; Rivaroxaban; Thiophenes; Warfarin | 2015 |
Synthesis and Cytotoxic Evaluation of Pyran, Dihydropyridine and Thiophene Derivatives of 3-Acetylcoumarin.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coumarins; Dihydropyridines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pyrans; Structure-Activity Relationship; Thiophenes | 2015 |
Neither dabigatran nor rivaroxaban were linked to increased GI bleeding compared with warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin | 2015 |
Point-of-Care Warfarin Monitoring in the ROCKET AF Trial.
Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin | 2016 |
Response to the letter concerning the article "Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients".
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Follow-Up Studies; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2016 |
Point-of-Care Warfarin Monitoring in the ROCKET AF Trial.
Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin | 2016 |
Point-of-Care Warfarin Monitoring in the ROCKET AF Trial.
Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin | 2016 |
Original research paper. Synthesis and antitumor activity of some novel thiophene, pyrimidine, coumarin, pyrazole and pyridine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Coumarins; Humans; Pyrazoles; Pyridines; Pyrimidines; Structure-Activity Relationship; Thiophenes | 2017 |
Present status and future orientation of rivaroxaban application in patients with nonvulvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2017 |
Synthesis of Novel Thiophene, Thiazole and Coumarin Derivatives Based on Benzimidazole Nucleus and Their Cytotoxicity and Toxicity Evaluations.
Topics: Anilides; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Coumarins; Decapoda; Drug Screening Assays, Antitumor; Humans; Larva; Quinolines; Structure-Activity Relationship; Thiazoles; Thiophenes | 2018 |
Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Coumarins; Drug Discovery; Fluorescence; Humans; Membrane Potential, Mitochondrial; Mice; Mitochondria; Molecular Docking Simulation; Phosphorylation; Reactive Oxygen Species; Serine; STAT3 Transcription Factor; Thiophenes; Tyrosine | 2019 |
Anti-proliferative, c-Met Inhibitions, and PAINS Evaluations of New Thiophene, Thiazole, Coumarin, Pyran, and Pyridine Derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coumarins; Cyclohexanes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Protein Kinase Inhibitors; Pyrans; Pyridines; Structure-Activity Relationship; Thiazoles; Thiophenes | 2022 |
Novel thiophene Chalcones-Coumarin as acetylcholinesterase inhibitors: Design, synthesis, biological evaluation, molecular docking, ADMET prediction and molecular dynamics simulation.
Topics: Acetylcholinesterase; Alzheimer Disease; Cells, Cultured; Chalcone; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Thiophenes | 2022 |